ROLE OF "ATYPICAL" MICROORGANISMS ON THE FORMATION OF BRONCHIAL ASTHMA IN CHILDREN WITH ACUTE AND RECURRENT OBSTRUCTIVE BRONCHITIS
Objective: This study was undertaken to determine the link between the presence of atypicalâ€ infections in patients with acute obstructive and
recurrent obstructive bronchitis (AOB/ROB) and bronchial asthma (BA) development based on the concept of risk.
Methods: The materials for the study were the data records of patients hospitalized with AOB or ROB and whose analysis was performed to identify
antibodies to atypicalâ€ microflora (796 patients). The study period was 4 years from 2008 to 2011. In the analyzed period, immunosorbent assay for
the detection of antibodies to atypicalâ€ microflora (Chlamydophila pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis) was performed. The
concept of risk identification was based on the determination of the absolute risk, attributable risk (AtR), relative risk, population attributable risk, as
well as on the definition of the standard errors for each type of risk and the confidence interval.
Results and Conclusion: Methodical aspects of determining the relationship between the presence of atypicalâ€ infections in patients with AOB
or ROB and BA development were based on the concept of risk. The analysis showed a direct link between the increase of cases of BA formation
against the backdrop of atypicalâ€ infections. Therefore, the performed analysis of atypical pathogens influences on BA occurrence in patients with
AOB/ROB which indicates direct dependence increase of BA incidence on atypical infection. In experimental group, Frequency of event is 14.84% in
experimental group. Frequency of event is 1.67% in control group. The risk factor increases probability of event by 13.17%, the risk factor increases
probability of event by 13.17%. Presence of atypical infection leads to increase of BA incidence by 8.9 times. Number needed to harm (NNH) is 7.59,
i.e., in the presence of atypical infection in patients with AOB/ROB, each eighth exposed person develops BA in addition to background level of BA
Keywords: Acute obstructive bronchitis, Recurrent obstructive bronchitis, Bronchial asthma, The concept of risk, Risk factor, The absolute risk,
Relative risk, Attributable risk, Population attributable risk, Number needed to harm.
2. Geppe NÐ. Topicality of bronchial asthma in children. Pediatriya 2012;3:76-82.
3. Sereda EV, Lukina OF, Selimzyanova LR. Mechanisms of bronchial obstruction and therapeutic tactics for bronchitis in children. Pediatriya 2010;5:77-86.
4. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, GÃ¶tz M, et al. Diagnosis and treatment of asthma in childhood: A PRACTALL consensus report. Allergy 2008;63(1):5-34.
5. Zhukova OV, Konyshkina TM, Kononova SV. The concept of risk factors in assessing the impact of smoking on an exacerbation of chronic obstructive pulmonary disease. Ter Arkh 2015;87(3):23-6.
6. Dzh B. Infections of Respiratory Tract. Moscow, Saint Petersburg: BINOM, Nevskiy dialekt. 2000. p. 192.
7. Samsygina GA. Antibiotics in the treatment of acute bronchitis in children. Lech Vrach 2001;1:12-5.
8. Cook PJ, Honeybourne D. Clinical aspects of Chlamydia pneumoniae infection. Presse Med 1995;24:278-82.
9. Woodcock A, Lowe LA, Murray CS, Simpson BM, Pipis SD, Kissen P, et al. Early life environmental control: Effect on symptoms, sensitization, and lung function at age 3 years. Am J Respir Crit Care Med 2004;170:433-9.
10. Dietzsch HJ, Rupprecht E, Wunderlich P. Epidemiologic and bronchologic aspects of chronic bronchitis in childhood (authorâ€™s transl). Padiatr Padol 1975;10(2):176-83.
11. Hahn DL. Antichlamydial antimicrobial therapy for asthma. Arch Pediatr Adolesc Med 1995;149(2):219-21.
12. Zaytseva OV. Problems of diagnosis and treatment of respiratory infections caused by atypicalâ€ pathogens. Trudnyy Patsient 2010;9:4-8.
13. Zhukova OV, Konyshkina TM, Kononova SV. Fishburneâ€™s method and the classical method of pharmacoeconomic analysis in the evaluation of antibiotic treatment of acute and recurrent bronchitis in children. Int J Pharm Pharm Sci 2015;7(11):185-90.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.